Active CMV and EBV infections in renal transplant recipients with unexplained fever and elevated serum creatinine

References

• Erfanianahmadpoor M, Nasiri R, Vakili R, Hassannia T. Seroprevalence, transmission, and associated factors of specific antibodies against cytomegalovirus among pregnant women and their infants in a regional study. Saudi Med J. 2014;35(4):360–364.
   PubMed Web of Science ®Google Scholar
• Cukuranovic J, Ugrenovic S, Jovanovic I, Visnjic M, Stefanovic V. Viral infection in renal transplant recipients. Sci World J. 2012;2012:820621.
   Web of Science ®Google Scholar
• Fishman JA. Infection in renal transplant recipients. Semin Nephrol. 2007;27(4):445–461.
   PubMed Web of Science ®Google Scholar
• Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis. 2008;47(5):702–711.
   PubMed Web of Science ®Google Scholar
• So S. CMV and EBV-PTLD after liver transplantation. Transplant Proc. 2001;33(1–2):1317–1319.
   PubMed Web of Science ®Google Scholar
• Hughes D, Hafferty J, Fulton L, et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: An analysis of 486 patients. J Clin Virol. 2008;41(2):92–95.
   PubMed Web of Science ®Google Scholar
• Khameneh ZR. Occurrence of cytomegalovirus infection and factors causing reactivation of the infection among renal transplant recipients: a single center study. Saudi J Kidney Dis Transpl. 2008;19(1):41–45.
   PubMedGoogle Scholar
• Li H, Dummer JS, Estes WR, Meng S, Wright PF, Tang YW. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol. 2003;41(1):187–191.
   PubMed Web of Science ®Google Scholar
• Abe T, Shinohara N, Tada M, et al. Infiltration of Epstein-Barr virus-harboring lymphocytes occurs in a large subset of bladder cancers. Int J Urol. 2008;15(5):429–434.
   PubMed Web of Science ®Google Scholar
• Allen U, Alfieri C, Preiksaitis J, et al. Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis. 2002;13(2):89–99.
   PubMedGoogle Scholar
• Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006;82(2 Suppl):S15–S17.
   Google Scholar
• Piiparinen H, Hockerstedt K, Gronhagen-Riska C, Lautenschlager I. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol. 2004;30(3):258–266.
   PubMed Web of Science ®Google Scholar
• Abou-El-Yazed E, El-Hoseny IM, Kasim K, El-Sadek AA, Morsy Amar A. Prevalence of cytomegalovirus infection among patients undergoing hemodialysis. Egypt J Immunol. 2008;15(2):33–41.
   PubMedGoogle Scholar
• Lijfering WM, de Vries AP, Veeger NJ, van Son WJ, Bakker SJ, van der Meer J. Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation. Thromb Hemost. 2008;99(1):127–132.
   PubMed Web of Science ®Google Scholar
• Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: A report of the FK506 Kidney. Transplant Study Group. Transplantation. 1998;66(12):1736–1740.
   PubMed Web of Science ®Google Scholar
• Nitsche A, Oswald O, Steuer N, et al. Quantitative real-time PCR compared with pp65 antigen detection for cytomegalovirus (CMV) in 1122 blood specimens from 77 patients after allogeneic stem cell transplantation: Which test better predicts CMV disease development? Clin Chem. 2003;49(10):1683–1685.
   PubMed Web of Science ®Google Scholar
• Siennicka J. Comparison of quantitative methods of DNA CMV investigation in clinical samples obtained from symptomatic and asymptomatic patients undergo renal transplantation. Med Dosw Mikrobiol. 2008;60(2):155–161.
   PubMedGoogle Scholar
• Guiver M, Fox AJ, Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation. 2001;71(11):1609–1615.
   PubMed Web of Science ®Google Scholar
• Michelson P, Watkins B, Webber SA, Wadowsky R, Michaels MG. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR. Pediatr Transplant. 2008;12(4):464–468.
   PubMed Web of Science ®Google Scholar
• Madi N, Al-Nakib W, Mustafa AS, Saeed T, Pacsa A, Nampoory MR. Detection and monitoring of cytomegalovirus infection in renal transplant patients by quantitative real-time PCR. Med Princ Pract. 2007;16(4):268–273.
   PubMed Web of Science ®Google Scholar
• Pacsa AS, Essa S, Voevodin A, et al. Correlation between CMV genotypes, multiple infections with herpesviruses (HHV-6, 7) and development of CMV disease in kidney recipients in Kuwait. FEMS Immunol Med Microbiol. 2003;35(2):125–130.
   PubMedGoogle Scholar
• Webb L, Casula A, Ravanan R, Tomson CR. UK Renal Registry 12th Annual Report (December 2009): Chapter 5: Demographic and biochemistry profile of kidney transplant recipients in the UK in 2008: National and centre-specific analyses. Nephron Clin Pract. 2010;115 (Suppl 1):c69–c102.
   Google Scholar
• Alberu J, Morales-Buenrostro LE, Correa-Rotter R, et al. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy. Rev Invest Clin. 2008;60(5):365–374.
   PubMedGoogle Scholar
• Allison SJ. Transplantation: Integrative peptidomics identifies acute renal-transplant rejection biomarkers. Nat Rev Nephrol. 2010;6(5):249.
   Google Scholar
• Bedke J, Stenzl A. Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol. 2010;7(6):339–347.
   PubMed Web of Science ®Google Scholar
• Fontaine A, Thuret R, Garrigues V, Taourel P. Post-transplant renal tumors: a report of three cases J Radiol. 2010;91(4):491–494.
   PubMedGoogle Scholar
• Guirado L, Ruiz JC, Andres A, et al. Results of renal re-transplant in Spain (1990-2002). NDT Plus. 2010;3(Suppl 2):ii37–ii40.
   PubMedGoogle Scholar
• Ruell J, Barnes C, Mutton K, et al. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transpl. 2007;40(1):55–61.
   PubMed Web of Science ®Google Scholar
• Funch DP, Brady J, Ko HH, Dreyer NA, Walker AM. Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. Recent Results Cancer Res. 2002;159:81–88.
   PubMedGoogle Scholar
• Bravender T. Epstein-Barr virus, cytomegalovirus, and infectious mononucleosis. Adolesc Med State Art Rev. 2010;21(2):251-264–2ix.
   PubMedGoogle Scholar
• Wang X, Yang K, Wei C, Huang Y, Zhao D. Coinfection with EBV/CMV and other respiratory agents in children with suspected infectious mononucleosis. Virol J. 2010;7:247.
   PubMed Web of Science ®Google Scholar
• Razeghi E, Hadadi A, Mansor-Kiaei M, Molavi M, Khashayar P, Pourmand G. Clinical manifestation, laboratory findings, and the response of treatment in kidney transplant recipients with CMV infection. Transplant. Proc. 2007;39(4):993–996.
   Google Scholar
• Weikert BC, Blumberg EA. Viral infection after renal transplantation: surveillance and management. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S76–S86.
   Google Scholar
• Pour-Reza-Gholi F, Labibi A, Farrokhi F, Nafar M, Firouzan A, Einollahi B. Signs and symptoms of cytomegalovirus disease in kidney transplant recipients. Transplant Proc. 2005;37(7):3056–3058.
   PubMed Web of Science ®Google Scholar
• Li C, Samaranayake NR, Ong KL, Wong HK, Cheung BM. Is human cytomegalovirus infection associated with hypertension? The United States National Health and Nutrition Examination Survey 1999-2002. PLoS One. 2012;7(7):e39760.
   Google Scholar